Long‐term outcomes with oral therapy in liver transplant recipients with hepatitis B-Reference-Cited by-同舟云学术

Long‐term outcomes with oral therapy in liver transplant recipients with hepatitis B

Published:2019-11-12 Issue:12 Volume:33 Page:
ISSN:0902-0063
Container-title:Clinical Transplantation
language:en
Short-container-title:Clin Transplant

Author:

Saab Sammy¹²³^ORCID,Song Dana²,Challita Youssef P.¹,Xiwen Zhou Tina¹,Saab Elena G.¹,Viramontes Matthew R.¹,Choi Gina¹²,Durazo Francisco A.¹²,Han Steven B.¹²,El Kabany Mohammed M.¹²,Jackson Nicholas J.⁴,Busuttil Ronald W.¹

Affiliation:

1. Department of Surgery University of California at Los Angeles Los Angeles California

2. Department of Medicine University of California at Los Angeles Los Angeles California

3. Department of Nursing University of California at Los Angeles Los Angeles California

4. Department of Medicine Statistics Core University of California at Los Angeles Los Angeles California

Funder

National Institutes of Health

National Center for Advancing Translational Sciences

University of California, Los Angeles

Publisher

Wiley

Subject

Transplantation

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/ctr.13740

Reference35 articles.

1. Requirements for global elimination of hepatitis B: a modelling study

2. Long-Term Outcomes in Hepatitis B: The REVEAL-HBV Study

3. Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B

4. Long-Term Treatment With Entecavir Induces Reversal of Advanced Fibrosis or Cirrhosis in Patients With Chronic Hepatitis B

5. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Role of Antiviral Prophylaxis in Preventing HBV and HDV Recurrence in the Setting of Liver Transplantation;Viruses;2023-04-23

2. Converting from Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in Patients with Hepatitis B Following Liver Transplantation;Annals of Transplantation;2023-03-16

3. Renal Outcomes With Tenofovir Alafenamide in Liver Transplant Recipients;Clinical Gastroenterology and Hepatology;2023-02

4. Tenofovir alafenamide prophylaxis post-liver transplantation: a real-world study in patients with chronic kidney disease;Acta Gastro Enterologica Belgica;2022-06

5. Eliminating viral hepatitis in children after liver transplants: How to reach the goal by 2030;World Journal of Gastroenterology;2022-01-21